ReviewFrontiers in oncology2022
Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Article
- Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review.Frontiers in immunology · 2026Review
- Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review.Frontiers in oncology · 2026Article
- Primary neuroendocrine tumor of the breast: A case report.Oncology letters · 2025Article
- Primary Neuroendocrine Carcinoma of Breast: Changing Paradigm.Indian journal of surgical oncology · 2025Article
- Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Frontiers in medicine · 2025Article
- Primary Neuroendocrine Tumor of the Breast: A Rare Case.Case reports in surgery · 2025Article
- Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions.Cancer reports (Hoboken, N.J.) · 2024Review
- Primary Large-Cell Neuroendocrine Carcinoma of the Breast.Diagnostics (Basel, Switzerland) · 2024Article
- Neuroendocrine neoplasms of the breast: a review of literature.Virchows Archiv : an international journal of pathology · 2024Review
- CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report.Clinical case reports · 2024Article
- Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.Cancers · 2024Review
- Histopathological Features Predicting Neuroendocrine Morphology in Primary Breast Tumors: A Retrospective Analysis.European journal of breast health · 2024Article
- [Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center's experience of a heterogenous entity.Frontiers in endocrinology · 2024Article
- Comparison of clinical characteristics and outcomes in primary neuroendocrine breast carcinoma versus invasive ductal carcinoma.Frontiers in oncology · 2024Article
- High frequency of alternative splicing variants of the oncogene Focal Adhesion Kinase in neuroendocrine tumors of the pancreas and breast.Frontiers of medicine · 2023Article
- Primary Breast Small Cell Carcinoma With Merkel Cell Features: A Case Report and Literature Review.Journal of breast cancer · 2023Article
- Primary neuroendocrine breast cancer-an unusual occurrence.Ecancermedicalscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary neuroendocrine carcinoma of the breast (NECB) is characterized with heterogeneity, rarity, and poor differentiation, which is probably an underestimated subtype of breast cancer, including small cell NECs and large cell NECs. The diagnostic criteria for NECB have been constantly updated as the disease changes and the understanding increases. According to the latest WHO Classification, primary neuroendocrine neoplasm (NEN) of the breast consists of well-differentiated neuroendocrine tumors (NET), extremely aggressive neuroendocrine carcinomas (NEC) as well as invasive breast cancers of no special type (IBCs-NST) with neuroendocrine differentiation. The accurate diagnosis of NECB remains a challenge for its low incidence, which needs multi-disciplinary methods. For the rarity of the disease, there is a lack of large samples and prospective clinical research. For these invasive tumors, there are no standardized therapeutic guidelines or norms, and the treatment often refers to nonspecific breast cancer. In addition, the prognosis of such patients remains unknown. In 2003, the World Health Organization (WHO) listed NECB as an independent entity for the first time, while few features of NECB were clarified. In this review, it presents the WHO Classification, clinicopathologic characteristics, diagnosis, treatment, and prognosis of these patients. In addition, it summarizes the latest studies on molecular features of NECB, aiming to provide new therapeutic perspectives for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.